Results 2,461-2,480 of 3,998 for speaker:Michael Harty
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I thank Deputy Kelly. Deputy O'Reilly is next.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I invite Mr. Mitchell to respond.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: The committee's report made a recommendation that there would be a review of the 2013 Act to see whether there was any legislative barrier to the process. Have the witnesses been able to identify any legislative barrier in the Act that inhibits the provision of orphan drugs?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: At a previous hearing, a recommendation or suggestion was made that orphan drugs need to be dealt with differently to standard drugs but the legislation does not allow for a distinction between a standard or common drug and an orphan drug. A recommendation was made that the legislation would be reviewed to see whether amendments to the legislation were necessary to allow a different process...
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I will allow the Deputy back in to expand on that in a few minutes. I thank the witnesses for those responses.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I am conscious of the fact that we have the HSE and the NCPE outside. Was there a specific question in that?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: On behalf of the committee, I thank Mr. Watt, Ms McGrath and Mr. Mitchell for coming to give their evidence. Of course, they can wait and observe the next session.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: The committee will now continue its consideration of the implementation of the recommendations contained in the report on the evaluation of orphan drugs which was published last February. On its behalf, from the HSE I welcome Professor Michael Barry, clinical director of the National Centre for Pharmacoeconomics; Mr. John Hennessy, national director of acute strategy and planning; and Mr....
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Was this submitted?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: When was that?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Was it submitted this morning?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Does Mr. Flanagan wish to contribute?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I thank Mr Hennessy. I will now move to Deputy Kelly.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: The Deputy should conclude her questioning.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I invite Professor Barry to respond first.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: We will have a brief answer from Mr. Hennessy and then we will have to move on.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: I appreciate that. The Deputy has made it very clear. Deputy Brassil is next.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Perhaps the witnesses will bank those questions while Senator Colm Burke makes his contribution.
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: Does that refer to committee recommendation No. 5 to appoint of an independent academic with knowledge of pricing and reimbursement to conduct a review of the current process and the role of orphan drug availability in Ireland? Is that the review to which Mr. Judge is referring to?
- Joint Oireachtas Committee on Health: Evaluating Orphan Drugs: Discussion (Resumed) (21 Nov 2018)
Michael Harty: That recommendation was that it would be an independent academic, but what is being proposed by Mr. Judge is an internal review within the Department.